Baccarani, M. Et Al. 2009. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. BLOOD , vol.113, no.19 , 4497-4504.

Baccarani, M., Rosti, G., Castagnetti, F., Haznedaroglu, I., Porkka, K., Abruzzese, E., ... Alimena, G.(2009). Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. BLOOD , vol.113, no.19, 4497-4504.

Baccarani, Michele Et Al. "Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study," BLOOD , vol.113, no.19, 4497-4504, 2009

Baccarani, Michele Et Al. "Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study." BLOOD , vol.113, no.19, pp.4497-4504, 2009

Baccarani, M. Et Al. (2009) . "Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study." BLOOD , vol.113, no.19, pp.4497-4504.

@article{article, author={Michele Baccarani Et Al. }, title={Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study}, journal={BLOOD}, year=2009, pages={4497-4504} }